Table 2.
The prevalence of MetS in T2DM, LADA, and T1DM.
| Study | Country | Type of study | Number of sample size | Age range, yr | Definitions of MetS | MetS (%) | Mean BMI(kg/m2)(mean ± SD) | Overweight or obesity(%) | Low HDL(%) | HighTG(%) | High BP(%) | Waist circumference(%) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T2D | LADA | T1D | ||||||||||||
| Lee et al. (17) | Korea | Clinical based | 1,370 | 47–62 | NCEP ATP III | 72.9 | 47.1 | n/d | 23.1 ± 3.7 | n/d | n/d | n/d | n/d | n/d |
| LADA China study (2013) | China | Multicenter, clinical based | 5,324 | ≥30 | NCEP ATP III | 75.6 | 62.0 | n/d | 23.9 ± 3.7 | 35.9 | 62.4 | 34.1 | n/d | |
| Xia Li et al. (30) | China | Multicenter, clinical based | 15,492 | ≥30 | CDS (2017) |
68.1 | 44.3 | 34.2 | n/d | n/d | 29.3 | 33.9 | 47.9 | 31.7 |
| ADOPT (2004) | USA, Europe | Multicenter, clinical based | 4,357 | 30–75 | NCEP ATP III | 83.7 | 74.1 | n/d | 31.4 ± 0.5 | n/d | n/d | n/d | n/d | n/d |
| NIRAD (2007) | Italy | Multicenter, clinical based | 4,250 | 30–75 | NCEP ATP III | 67.6 | 58.6 | n/d | 27.0 ± 5.2 | n/d | n/d | n/d | n/d | n/d |
| Action LADA 3 (2009) | Europe | Multicenter, clinical based | 2,011 | 30–70 | NCEP ATP III | 88.8 | 41.9 | 31.9 | n/d | n/d | n/d | n/d | n/d | n/d |
| Hawa et al. (24) | Europe | Multicenter, clinical based | 2,838 | 40–75 | IDF | 80.4 | 63.6 | n/d | 27.3 ± 3.6 | n/d | n/d | n/d | n/d | 67.6 |
Ab, antibody; ATP, National Cholesterol Education Program Adult Treatment Panel III; CDS, Chinese Diabetes Society; IDF, International Diabetes Federation; BP, blood pressure; HDL, high-density lipoprotein; n/d, no data; MetS, metabolic syndrome; T2DM, type 2 diabetes mellitus; LADA, latent autoimmune diabetes in adults; T1DM, type 1 diabetes mellitus; TG, triglycerides.